These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
225 related articles for article (PubMed ID: 37277193)
1. Outcomes and a prognostic classifier in patients with microsatellite instability-high metastatic gastric cancer receiving PD-1 blockade. Randon G; Aoki Y; Cohen R; Provenzano L; Nasca V; Klempner SJ; Maron SB; Cerantola R; Chao J; Fornaro L; Ferrari Bravo W; Ghelardi F; Ambrosini M; Manca P; Salati M; Kawazoe A; Zhu V; Cowzer D; Genovesi V; Lonardi S; Shitara K; André T; Pietrantonio F J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37277193 [TBL] [Abstract][Full Text] [Related]
2. Ascites and resistance to immune checkpoint inhibition in dMMR/MSI-H metastatic colorectal and gastric cancers. Fucà G; Cohen R; Lonardi S; Shitara K; Elez ME; Fakih M; Chao J; Klempner SJ; Emmett M; Jayachandran P; Bergamo F; García MD; Mazzoli G; Provenzano L; Colle R; Svrcek M; Ambrosini M; Randon G; Shah AT; Salati M; Fenocchio E; Salvatore L; Chida K; Kawazoe A; Conca V; Curigliano G; Corti F; Cremolini C; Overman M; Andre T; Pietrantonio F J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35110358 [TBL] [Abstract][Full Text] [Related]
3. Prognostic impact of performance status on the outcomes of immune checkpoint inhibition strategies in patients with dMMR/MSI-H metastatic colorectal cancer. Mazzoli G; Cohen R; Lonardi S; Corti F; Elez E; Fakih M; Jayachandran P; Colle R; Shah AT; Salati M; Fenocchio E; Salvatore L; Ambrosini M; Ros J; Intini R; Cremolini C; Overman MJ; André T; Pietrantonio F Eur J Cancer; 2022 Sep; 172():171-181. PubMed ID: 35777274 [TBL] [Abstract][Full Text] [Related]
4. Tumour mutational burden as a biomarker in patients with mismatch repair deficient/microsatellite instability-high metastatic colorectal cancer treated with immune checkpoint inhibitors. Manca P; Corti F; Intini R; Mazzoli G; Miceli R; Germani MM; Bergamo F; Ambrosini M; Cristarella E; Cerantola R; Boccaccio C; Ricagno G; Ghelardi F; Randon G; Leoncini G; Milione M; Fassan M; Cremolini C; Lonardi S; Pietrantonio F Eur J Cancer; 2023 Jul; 187():15-24. PubMed ID: 37099945 [TBL] [Abstract][Full Text] [Related]
5. The Prognostic Nutritional Index in patients with microsatellite instability-high metastatic gastric or gastroesophageal cancers receiving immune checkpoint inhibitors. Ghelardi F; Fucà G; Cavalli C; Shitara K; Cohen R; Ambrosini M; Maron SB; Cerantola R; Nasca V; Liberti GD; Zambelli L; Palazzo M; Salati M; Aoki Y; Kawazoe A; Cowzer D; Lonardi S; André T; Randon G; Pietrantonio F Dig Liver Dis; 2024 May; ():. PubMed ID: 38772790 [TBL] [Abstract][Full Text] [Related]
6. Effectiveness of PD-1 inhibitor-based first-line therapy in Chinese patients with metastatic gastric cancer: a retrospective real-world study. Duan Y; Li J; Zhou S; Bi F Front Immunol; 2024; 15():1370860. PubMed ID: 38933261 [TBL] [Abstract][Full Text] [Related]
8. Clinical and Molecular Predictors of Response to Immune Checkpoint Inhibitors in Patients with Advanced Esophagogastric Cancer. Greally M; Chou JF; Chatila WK; Margolis M; Capanu M; Hechtman JF; Tuvy Y; Kundra R; Daian F; Ladanyi M; Kelsen DP; Ilson DH; Berger MF; Tang LH; Solit DB; Diaz LA; Schultz N; Janjigian YY; Ku GY Clin Cancer Res; 2019 Oct; 25(20):6160-6169. PubMed ID: 31337644 [TBL] [Abstract][Full Text] [Related]
9. Subcutaneous envafolimab monotherapy in patients with advanced defective mismatch repair/microsatellite instability high solid tumors. Li J; Deng Y; Zhang W; Zhou AP; Guo W; Yang J; Yuan Y; Zhu L; Qin S; Xiang S; Lu H; Gong J; Xu T; Liu D; Shen L J Hematol Oncol; 2021 Jun; 14(1):95. PubMed ID: 34154614 [TBL] [Abstract][Full Text] [Related]
10. Adjuvant Chemotherapy for Gastric Cancer Patients with Mismatch Repair Deficiency or Microsatellite Instability: Systematic Review and Meta-Analysis. Nie RC; Chen GM; Yuan SQ; Kim JW; Zhou J; Nie M; Feng CY; Chen YB; Chen S; Zhou ZW; Wang Y; Li YF Ann Surg Oncol; 2022 Apr; 29(4):2324-2331. PubMed ID: 34796431 [TBL] [Abstract][Full Text] [Related]
11. Prognostic and Predictive Value of Microsatellite Instability, Inflammatory Reaction and PD-L1 in Gastric Cancer Patients Treated with Either Adjuvant 5-FU/LV or Sequential FOLFIRI Followed by Cisplatin and Docetaxel: A Translational Analysis from the ITACA-S Trial. Di Bartolomeo M; Morano F; Raimondi A; Miceli R; Corallo S; Tamborini E; Perrone F; Antista M; Niger M; Pellegrinelli A; Randon G; Pagani F; Martinetti A; Fucà G; Pietrantonio F; Oncologist; 2020 Mar; 25(3):e460-e468. PubMed ID: 32162808 [TBL] [Abstract][Full Text] [Related]
12. Efficacy of immune-checkpoint inhibitors in metastatic gastric or gastroesophageal junction adenocarcinoma by patient subgroups: A systematic review and meta-analysis. Kundel Y; Sternschuss M; Moore A; Perl G; Brenner B; Goldvaser H Cancer Med; 2020 Oct; 9(20):7613-7625. PubMed ID: 32869544 [TBL] [Abstract][Full Text] [Related]
13. Factors Modifying the Associations of Single or Combination Programmed Cell Death 1 and Programmed Cell Death Ligand 1 Inhibitor Therapies With Survival Outcomes in Patients With Metastatic Clear Cell Renal Cell Carcinoma: A Systematic Review and Meta-analysis. Sati N; Boyne DJ; Cheung WY; Cash SB; Arora P JAMA Netw Open; 2021 Jan; 4(1):e2034201. PubMed ID: 33496794 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of Immune Checkpoint Inhibitors in Patients with Microsatellite Instability-High End-Stage Cancers and Poor Performance Status Related to High Disease Burden. Pietrantonio F; Loupakis F; Randon G; Raimondi A; Salati M; Trapani D; Pagani F; Depetris I; Maddalena G; Morano F; Corallo S; Prisciandaro M; Corti F; Guarini V; Bocconi A; Marra A; Belli C; Spallanzani A; Fassan M; Lonardi S; Curigliano G; Fucà G; Di Bartolomeo M; de Braud F Oncologist; 2020 Sep; 25(9):803-809. PubMed ID: 32369650 [TBL] [Abstract][Full Text] [Related]
15. Combination of AKT1 and CDH1 mutations predicts primary resistance to immunotherapy in dMMR/MSI-H gastrointestinal cancer. Wang Z; Zhang Q; Qi C; Bai Y; Zhao F; Chen H; Li Z; Wang X; Chen M; Gong J; Peng Z; Zhang X; Cai J; Chen S; Zhao X; Shen L; Li J J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35705314 [TBL] [Abstract][Full Text] [Related]
16. The Pan-Immune-Inflammation Value in microsatellite instability-high metastatic colorectal cancer patients treated with immune checkpoint inhibitors. Corti F; Lonardi S; Intini R; Salati M; Fenocchio E; Belli C; Borelli B; Brambilla M; Prete AA; Quarà V; Antista M; Fassan M; Morano F; Spallanzani A; Ambrosini M; Curigliano G; de Braud F; Zagonel V; Fucà G; Pietrantonio F Eur J Cancer; 2021 Jun; 150():155-167. PubMed ID: 33901794 [TBL] [Abstract][Full Text] [Related]
17. Individual Patient Data Meta-Analysis of the Value of Microsatellite Instability As a Biomarker in Gastric Cancer. Pietrantonio F; Miceli R; Raimondi A; Kim YW; Kang WK; Langley RE; Choi YY; Kim KM; Nankivell MG; Morano F; Wotherspoon A; Valeri N; Kook MC; An JY; Grabsch HI; Fucà G; Noh SH; Sohn TS; Kim S; Di Bartolomeo M; Cunningham D; Lee J; Cheong JH; Smyth EC J Clin Oncol; 2019 Dec; 37(35):3392-3400. PubMed ID: 31513484 [TBL] [Abstract][Full Text] [Related]
18. Predictive role of microsatellite instability for PD-1 blockade in patients with advanced gastric cancer: a meta-analysis of randomized clinical trials. Pietrantonio F; Randon G; Di Bartolomeo M; Luciani A; Chao J; Smyth EC; Petrelli F ESMO Open; 2021 Feb; 6(1):100036. PubMed ID: 33460964 [TBL] [Abstract][Full Text] [Related]
19. The Optimal Therapy after Progression on Immune Checkpoint Inhibitors in MSI Metastatic Gastrointestinal Cancer Patients: A Multicenter Retrospective Cohort Study. Chen M; Wang Z; Liu Z; Liu N; Fang W; Zhang H; Jin X; Li J; Zhao W; Qu H; Song F; Chang Z; Li Y; Tang Y; Xu C; Zhang X; Wang X; Peng Z; Cai J; Li J; Shen L Cancers (Basel); 2022 Oct; 14(20):. PubMed ID: 36291942 [TBL] [Abstract][Full Text] [Related]
20. Prognosis and chemosensitivity of deficient MMR phenotype in patients with metastatic colorectal cancer: An AGEO retrospective multicenter study. Tougeron D; Sueur B; Zaanan A; de la Fouchardiére C; Sefrioui D; Lecomte T; Aparicio T; Des Guetz G; Artru P; Hautefeuille V; Coriat R; Moulin V; Locher C; Touchefeu Y; Lecaille C; Goujon G; Ferru A; Evrard C; Chautard R; Gentilhomme L; Vernerey D; Taieb J; André T; Henriques J; Cohen R; Int J Cancer; 2020 Jul; 147(1):285-296. PubMed ID: 31970760 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]